Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 9485Neoplasms 6599Prostatic Neoplasms 4404Colorectal Neoplasms 3979Lung Neoplasms 3647Carcinoma, Non-Small-Cell Lung 3587Pancreatic Neoplasms 2480Carcinoma, Hepatocellular 2416Leukemia, Myeloid, Acute 2266Multiple Myeloma 2123Stomach Neoplasms 2109Neoplasm Metastasis 1913Head and Neck Neoplasms 1873Ovarian Neoplasms 1778Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1731Brain Neoplasms 1706Rectal Neoplasms 1676Melanoma 1657Colonic Neoplasms 1629Uterine Cervical Neoplasms 1501Leukemia 1500Recurrence 1486Esophageal Neoplasms 1312Glioblastoma 1310Lymphoma, Non-Hodgkin 1205Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1080Lymphoma, Follicular 1069

Interventions

sodium glycididazole 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Chemoradiotherapy × Clear all
NCT06667622 2024-10-31

Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
40 enrolled

Chemoradiotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡